USING SURFACTANT IN THE TREATMENT OF PATIENTS WITH PULMONARY TUBERCULOSIS

Abstract

The experience of using the inhaled drug Surfactant-BL in patients with tuberculosis of the respiratory organs on the background of standard chemotherapy is presented, taking into account the drug sensitivity of Mycobacterium tuberculosis. The epidemic situation of tuberculosis in the Republic of Sakha (Yakutia) has positive trends: the incidence rate of tuberculosis has decreased by 1.6 times, amounting to 28.6 per 100,000 population in 2021; the prevalence of tuberculosis in the republic in 2021 reached 56.2 per 100,000 population (-34.8 % compared to 2019). Despite the decrease in tuberculosis bacillarity (by 1.5 times compared to 2019), the multidrug resistance (MDR) of the pathogen continues to remain at a fairly high level, amounting to 29.5 % – 31.7 %. Patients are prescribed chemotherapy with 5 anti-TB drugs, against the background of which inhalation of surfactant significantly facilitates sputum discharge, and therefore contributes to the rehabilitation of decay cavities, accelerates the disappearance of symptoms of tuberculosis intoxication.The article presents two clinical cases, demonstrating the effectiveness of complex therapy in a patient with newly diagnosed destructive tuberculosis of the respiratory system and a patient with diagnosed mycobacteriosis.